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Abstract
Objective: Maternal mortality (MM) is a core indicator of disparities in women’s rights. The study of Near Miss cases is
strategic to identifying the breakdowns in obstetrical care. In absolute numbers, both MM and occurrence of eclampsia are
rare events. We aim to assess the obstetric care indicators and main predictors for severe maternal outcome from eclampsia
(SMO: maternal death plus maternal near miss).
Methods: Secondary analysis of a multicenter, cross-sectional study, including 27 centers from all geographic regions of
Brazil, from 2009 to 2010. 426 cases of eclampsia were identified and classified according to the outcomes: SMO and non-
SMO. We classified facilities as coming from low- and high-income regions and calculated the WHO’s obstetric health
indicators. SPSS and Stata softwares were used to calculate the prevalence ratios (PR) and respective 95% confidence
interval (CI) to assess maternal characteristics, clinical and obstetrical history, and access to health services as predictors for
SMO, subsequently correlating them with the corresponding perinatal outcomes, also applying multiple regression analysis
(adjusted for cluster effect).
Results: Prevalence of and mortality indexes for eclampsia in higher and lower income regions were 0.2%/0.8% and 8.1%/
22%, respectively. Difficulties in access to health care showed that ICU admission (adjPR 3.61; 95% CI 1.77–7.35) and
inadequate monitoring (adjPR 2.31; 95% CI 1.48–3.59) were associated with SMO.
Conclusions: Morbidity and mortality associated with eclampsia were high in Brazil, especially in lower income regions.
Promoting quality maternal health care and improving the availability of obstetric emergency care are essential actions to
relieve the burden of eclampsia.
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Introduction
Eclampsia is a rare, however potentially life-threatening
complication of the hypertensive disorders (HD) of pregnancy,
accountable for large numbers in morbidity and deaths among
women of reproductive age and their offspring [1–4]. The estimate
of incidence and the burden of eclampsia is still a challenging
pursuit worldwide; currently only seven countries have national
data on the topic [5]. A systematic review on preeclampsia (PE)
and eclampsia, performed in 2013, indicated that the crude
incidence of eclampsia fluctuates from 0 to 0.1% in Europe and up
to 4% in Nigeria; Brazilian studies showed a 0.6% incidence [5,6].
Nonetheless, 94.6% of the data were collected in the USA,
highlighting a marked regionalization bias and, therefore, the need
for more studies, especially in low- and middle-income countries
(LMIC) [5,7].
The case fatality rate (number of deaths/number of cases) of
eclampsia ranges from 0–1.8% in high-income countries up to
17.7% in India, emphasizing a huge gap in the quality of maternal
health care according to social and economic patterns [8]. Over a
one-year period, the Swedish Medical Birth Register identified no
maternal death due to eclampsia, whilst in India, in the same
period, only one hospital reported 11 eclampsia-related deaths [8–
10].
Reducing maternal mortality (MM) by three quarters is one of
the United Nations’ Millennium Development Goals [11]. Nearly
the totality of women who die from pregnancy-related causes
comes from LMIC [2,3]. According to the Brazilian Ministry of
Health, there has been a substantial reduction of maternal deaths
(MD) in the country from 1990 to 2010, i.e., a decrease from 141
to 62 deaths for 100,000 live births (LB) [12]. Nevertheless, in
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order to achieve the MDG5 by 2015, Brazil would have to halve
this number, what seems to be a very difficult mission to pursue.
Recently, the World Health Organization (WHO) defined the
presence of organ dysfunction or failure during pregnancy,
childbirth or postpartum as maternal near miss (NM). A woman
who fulfills one of the clinical, laboratory or management criteria
established by WHO is a NM case. From a theoretical perspective,
the NM cases should be as similar to maternal deaths as possible
[13–17].
Childbirth care in LMIC is usually associated with difficult
access to adequate maternity services [2,3,7]. In Brazil, although
98% of pregnant women do deliver their babies in hospitals, a
large number of these facilities are not well equipped to deal with
pregnancy-related complications. The shortage of intensive care
units (ICU) to where such women can be transferred is still a
worrying reality in several settings [12]. In addition the proportion
of facilities with adequately trained staff to deal with complications
is not known at all.
MM is amongst the worst-performing health indicators in
resource-poor settings. In absolute numbers, both maternal
mortality and the occurrence of eclampsia are rare events
[2,3,16,17]. The only Brazilian national data on eclampsia is the
total number of deaths, 167 cases in 2010, with a maternal
mortality ratio (MMR) of 5.83 [18]. It is with the intent of filling
this epidemiological gap that our study aims to assess the obstetric
care indicators and main predictors for severe maternal outcomes
from eclampsia (SMO: maternal death plus maternal near miss).
Methods
Our study is a secondary analysis of The Brazilian Network for
Surveillance of Severe Maternal Morbidity Study. The purpose of
this network was to identify cases of severe maternal morbidity/
near miss, using the criteria recently established by WHO to
characterize these conditions [16]. According to this definition, a
maternal near miss case is a woman who experienced a very
serious complication during pregnancy and as a consequence
almost died, surviving at least until the 42nd day after childbirth.
The methods of the Brazilian Network have already been
described in details elsewhere [19,20].
Briefly, it was a cross-sectional multicenter study conducted
from July 2009 to June 2010, involving 27 hospitals from all
different regions of Brazil, excluding the Federal District. From
those 27 centers, 95% of cases were insured by SUS, the Brazilian
publicly funded health system. Brazil is geographically divided into
5 different regions and one Federal District: North (N), Northeast
(NE), Midwest (MW), South (S) and Southeast (SE). We assembled
these regions into 2 major groups, according to their 2000, human
development index (HDI) [21]. According to this definition, S and
SE were high HDI regions and N, NE and MD were low HDI
regions. We then calculated the indicators proposed by WHO to
monitor the quality of obstetric care using maternal near miss and
maternal death cases with eclampsia [16].
During this period, out of the 9,555 women who were
diagnosed with severe maternal complications, 6,706 presented
with severe hypertensive disorders and 426 were admitted with, or
developed, eclampsia during hospitalization. Eclampsia was
identified by the occurrence of tonic-clonic seizures - including
seizures and coma - that occurred during pregnancy, delivery or
puerperium and that were not related to preexisting organic brain
disorders [1].
Main Outcomes
Maternal outcomes for eclampsia during pregnancy, childbirth
or puerperium were considered in two different groups:
Non-Severe Maternal Outcome (non-SMO). All cases of
eclampsia in the absence of organ failure/dysfunction were
classified as non-SMO; this is the comparison group.
SMO (Severe maternal outcome). All cases of maternal
death or maternal near miss.
N Maternal Near Miss (NM): cases that fulfilled at least one of the
clinical, laboratory or management criteria representing life-
threatening conditions (i.e., organ failure/dysfunction) and
who survived this condition. Figure 1.
N Maternal Death (MD): death during pregnancy or within 42 days
post-partum, regardless length or site of pregnancy, from any
cause related to or aggravated by the pregnancy or its
management, yet not from accidental or incidental causes.
Covariates
Information on age, skin color, marital status, schooling and
parity were analyzed as possible predictors of SMO from
eclampsia, as they are already been identified in some studies as
predictors for eclampsia [4,22,23].
Previous disease was defined as any pathological condition
diagnosed before or during pregnancy, but not related to it.
Chronic hypertension was defined as the presence of high blood
pressure (BP) $140690 mmHg diagnosed before the 20th week of
pregnancy, after two measurements within a minimum interval of
4 hours, regardless of the use of medications [1].
We selected the most frequent associated complications during
admission period: hemorrhage, HELLP syndrome, severe hyper-
tension, pulmonary edema and severe sepsis. Coagulation
disorders, shock, jaundice concomitantly with preeclampsia and
cerebrovascular accident are part of the NM definition criteria,
and were therefore excluded from the analysis because of their
behavior as interacting variables.
The use of magnesium sulphate (MgSO4) for the prevention and
management of eclampsia was assessed as a dichotomous variable
(use and non-use) because the data collection form had no
information on the exact period of time when clinical events
occurred or procedures were performed, Therefore the opportu-
nity of its use could not be detailed assessed.
Post-partum admission was regarded as a worse outcome, based
upon the assumption that the eclamptic women who were
admitted after giving birth had to be transferred to a health
center capable of delivering a better care. Bearing in mind that not
all the Brazilian health facilities caring for pregnant women are
equipped with an ICU or have an ICU bed promptly available
(most ICUs operate at their full capacity at any given time), we had
to assume that only the most complicated cases of eclampsia were
admitted to ICU. In addition to this inference, ICU availability
was also assessed by the variable ‘‘inadequate monitoring’’,
translated into availability or not of ICU care.
Our study had local coordinators who were trained to gather
accurate information from both health care providers involved
with the care at its initial phases and from medical records, aiming
to address as many aspects of care as possible. We classified and
defined the variables ‘‘lack of drug’’, ‘‘inadequate monitoring’’,
‘‘delay for transfer’’, ‘‘lack of staff’’, ‘‘delay for diagnosis’’, ‘‘not
opportune treatment’’ and ‘‘inadequate management’’ to evaluate
the access to and quality of appropriate obstetric emergency care.
This was performed by both the local investigator and coordinator
and then checked by the study team of the coordinating center.
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We finally analyzed the perinatal outcomes and mode of
delivery in SMO cases. The variables were defined as follows: cut-
off point for gestational age at delivery, determined by clinical
criteria (less than 33 weeks and $34 weeks); mode of delivery,
listed as cesarean section or vaginal birth; perinatal outcome
(stillbirth or live birth); birth weight (,2500 or $2500 grams);
neonatal outcome (defined as neonatal ICU admission, neonatal
death, i.e., death until 28 days of life, or hospital discharge); fifth
minute Apgar score (,7 and from 7 to 10 indicates, respectively
low and high vitality score at birth); and perinatal death (stillbirth
plus neonatal death ,7 days).
Statistical Analysis
Bivariate analysis was performed to identify factors (predictors)
associated with SMO (maternal NM or MD) by estimating
prevalence ratios (PR) and their respective 95% confidence
intervals (CI), adjusted for cluster effect (maternal hospital or
centers) [24]. Access to health care facilities, maternal character-
istics, complications and procedures related to and/or used for
management of eclampsia, other than those already used for NM
case definition according to the WHO criteria, were described
comparatively among women from both groups, with differences
assessed by a Chi-square test. Additionally the hazard of perinatal
outcomes including the mode of delivery was also estimated for
women who progressed towards an SMO, with adjusted PR and
their respective 95% confidence interval (CI). Finally, Poisson
multiple regression analysis was performed in 321 cases in which
all variables were available and adjusted by cluster and all other
predictors. The primary sampling units of our study were the
health care facilities and therefore it was necessary to adjust the
analysis by the cluster effect [25]. The softwares used for the
analysis were SPSS version 17 (SPSS, Chicago, IL, USA) and
Stata version 7.0 (StataCorp, College Station, TX, USA).
Quality Control
The network database was fed with information extracted from
the medical records, transcribed manually onto the data collection
form by local investigators and later on transferred to the
electronic forms. The technical procedures for case selection and
accurate form filling were detailed explained in the respective
manual of operation. Local study coordinators performed
systematic quality control of data, so that possible incongruences
could be identified. One of the investigators from the coordinating
center visited the institutions taking part of this study, aiming to
verify the consistency of the information retrieved from both
manually- and electronically-filled collection forms in light of the
case reports of the study subjects, randomly selecting such cases.
The final quality control was performed by the application of
logical consistency and review of database.
Ethical Statement
This study is a secondary analysis; all records were obtained
through the database of the main study, the Brazilian Network for
Surveillance of Severe Maternal Morbidity. According to the rules
of the sponsor agency the database is not of public domain and the
principal investigators are the owners of the data, being
responsible for its use for scientific purposes. We followed all the
principles that regulate research on human beings defined by the
Brazilian National Health Council, as well as the Declaration of
Helsinki. There was no need for an Informed Consent Form, since
data were collected from medical records post–discharge or post-
mortem and no contact occurred with the subjects. Local IRBs
(listed below) and the National Committee of Ethics in Research
(CONEP, Brazilian Ministry of Health) approved the study, under
the letter of approval 097/2009. The National Council for Ethics
in Research and the Institutional Review Boards of each site
granted a waiver of individual informed consent.
Figure 1. WHO criteria for maternal near miss.
doi:10.1371/journal.pone.0097401.g001
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The Review Boards of the following institutions reviewed and
approved this study: Maternidade Cidade Nova Dona Nazarina
Daou (Manaus, AM), Maternidade Clime´rio de Oliveira (Salva-
dor, BA), Hospital Geral de Fortaleza (Fortaleza, CE), Hospital
Geral Dr. Ce´sar Cals (Fortaleza, CE), Maternidade Escola Assis
Chateaubriand (Fortaleza, CE), Hospital Materno Infantil de
Goiania (Goiania, GO), Hospital Universita´rio da Universidade
Federal do Maranhao (Sao Luis, MA), Maternidade Odete
Valadares (Belo Horizonte, MG), Instituto de Sau´de Elıdio de
Almeida (Campina Grande, PB), Hospital Universita´rio Lauro
Wanderley da Universidade Federal da Paraiba (Joao Pessoa, PB),
Centro Integrado de Sau´de Amaury de Medeiros (Recife, PE),
Instituto de Medicina Integral Prof. Fernando Figueira (Recife,
PE), Hospital das Clınicas da Universidade Federal de Pernam-
buco (Recife, PE), Hospital das Clınicas da Universidade Federal
do Parana´ (Curitiba, PR), Hospital Maternidade Fernando
Magalhaes (Rio de Janeiro, RJ), Instituto Fernandes Figueira
(Rio de Janeiro, RJ), Hospital das Clinicas da Universidade
Federal do Rio Grande do Sul (Porto Alegre, RS), Faculdade de
Medicina de Botucatu da Universidade Estadual Paulista
(Botucatu, SP), Hospital da Mulher da Universidade Estadual de
Campinas (Campinas, SP), Hospital e Maternidade Celso Pierro
da Pontifıcia Universidade Cato´lica (Campinas, SP), Hospital
Israelita Albert Einstein (Sa˜o Paulo, SP), Faculdade de Medicina
de Jundiaı´ (Jundiaı, SP), Hospital das Clınicas da Faculdade de
Medicina de Ribeira˜o Preto da Universidade de Sa˜o Paulo
(Ribeira˜o Preto, SP), Santa Casa de Limeira (Limeira, SP), Santa
Casa de Sa˜o Carlos (Sa˜o Carlos, SP), Casa Maternal Leonor
Mendes de Barros (Sa˜o Paulo, SP), Hospital Sa˜o Paulo da
Universidade Federal de Sa˜o Paulo (Sa˜o Paulo, SP).
Results
In the one-year study period, there were 82,388 women
admitted to the 27 maternity hospitals participating in the study;
these women gave birth to 82,144 live births (LB). 9,555 women
presented pregnancy-related severe complications and met the
study inclusion criteria. Out of this population, 910 women
progressed to SMO (770 maternal NM and 140 maternal deaths);
20% of cases of eclampsia, 4% of cases of other severe
hypertensive disorders (excluding eclampsia) and 17% of other
morbidities (infectious and hemorrhagic disorders) developed
SMO. Respectively, almost 4% of cases of eclampsia and other
morbidities and 0.4% of cases of other severe hypertensive
disorders died. (Figure 2).
The total prevalence of eclampsia was 5.2 (per 1000 LB) and a
specific MMR of 19.5 (per 100,000 LB). The total mortality index
was 18.6%, 2.7 times higher in the Brazilian regions of lower HDI:
22.6% gathering the Midwest, Northeast and North regions, and
8.3% for South and Southeast regions (Table 1).
Approximately 70% of all eclamptic women were primiparous.
The median age of the cases was 20 years, with the youngest being
13 and the eldest 44 (data not showed in tables). Amongst the
maternal characteristics, obstetric background and medical
history, the only factors associated with the risk of SMO from
eclampsia were any previous disease and chronic hypertension.
Medical histories of any previous disease were present in 27% of
the cases and almost doubled the risk of SMO (PR 1.86; CI 1.35–
2.57) (Table 2).
Moreover, the adequacy of the prenatal care received, indirectly
evaluated by the number of visits corrected for gestational age at
birth, was appropriate in more than 67% of the total number of
cases and the moment of hospital admission, if still during
pregnancy (80%) or after giving birth (20%), showed no
association with worse outcome amongst eclamptic women
(Table 3).
Variables used to evaluate the access to health care demon-
strated a robust association with the risk of SMO from eclampsia
(Table 3). ICU admission (PR 4.70; 95% CI 2.81–7.84),
inadequacies of monitoring (PR 2.94; 95% CI 2.13–4.07); delay
for transfer (PR 2.32; 95% CI 1.33–4.05); lack of trained staff (PR
1.88; 95% CI 1.20–2.93); delay for diagnosis (PR 2.29; 95% CI
Figure 2. Distribution of Non-SMO, MNM and MD in women with eclampsia, others SHD and other morbidities [Non-SMO=women
without severe maternal outcomes (MNM or MD), SMO=Severe maternal outcome (MNM=maternal near miss or MD=maternal
death), SHD= severe hypertensive disorders].
doi:10.1371/journal.pone.0097401.g002
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1.42–3.69), not opportune treatment (PR 2.27; 95% CI 1.48–3.46)
and inadequate management of the case (PR 1.86; 95% CI 1.33–
2.60) led to a two- to four-fold increased in the risk of SMO.
Poisson multiple regression analyses confirmed admission to
ICU, lack adequate monitoring, severe sepsis and any previous
disease as the main independent predictors for SMO. All
complications of pregnancy were strongly associated with
increased risk of SMO (data not presented in tables), despite the
fact that only severe sepsis, on the multiple regression analysis,
predicted SMO (adjusted PR 2.75; 95% CI 1.35–5.61) (Table 4).
Nevertheless, the incidence of such complications among eclamp-
tic women was not similar, fluctuating from 1% (pulmonary
edema) to 12% (HELLP). (Data not presented in tables.).
Gestational age at delivery reached a median of 36 weeks,
fluctuating from 22 to 42 weeks; birth weight implied a median of
2.410 grams, ranging from 520 to 4.900 grams (data not presented
in tables) and C-section accounted for 88% of all deliveries.
Perinatal outcomes were also substantially worse in the SMO
group: stillbirth (PR 2.34, 95% CI 1.29–4.24), neonatal ICU
admission (PR 1.84; 95% CI 1.09–3.10), neonatal death (PR 2.68;
95% CI 1.21–5.91), low 5-min Apgar score (PR 2.87; 95% CI
1.79–4.62) and perinatal death (PR 2.3; 95% CI 1.45–3.65)
(Table 5).
Discussion
Our study presents an overview of the clinical morbidities and
the access to health care for women with eclampsia in selected
obstetric units in the five geographical Brazilian regions. These
results confirm a prevalence of SMO for eclampsia five times
higher than for other severe hypertensive disorders of pregnancy
group (excluding cases of eclampsia). In fact, eclampsia is a major
cause of morbidity and death in this group. Multiple regression
analysis pointed out that the lack of emergency care facilities in
obstetric units are predictors of worse outcomes among women
with eclampsia. In addition, any previous disease and severe sepsis
were also main predictors of SMO from eclampsia. The higher
risk of dying found when ICU admission was present shows that
probably there was a pre-selection of most severe cases towards
admission to ICU, and the already well-known shortage of ICU
beds in many Brazilian health care facilities has a major impact on
this result [26].
Three quarters of the Brazilian population are insured by SUS,
the Brazilian publicly funded health system, and the remaining
one quarter relies on the insurance and/or private health sector.
The only center included in the Brazilian Network that provides
care exclusively to high-income private patients did not have any
case of eclampsia over this one-year period.
Our study has several strengths, including a broad geographical
distribution of the participating centers, assuring the representa-
tiveness of all regions (with 55.6% LB from the South and
Southeast, and 48.4% from the North, Northeast, and Midwest); a
rigorous three-step check for control of data quality, as described;
and a large sample size due to the eligibility of many of the cases.
We found a proportion of 9.5% of SMO for eclampsia among the
910 cases of SMO from the network, very close to that found by
the WHO Multicountry Survey (9.6%) undertaken in 29 countries
and 357 health facilities, recently published [27].
Figure 1 demonstrates that SMO was present in 20% of cases of
eclampsia and was responsible for the majority of SMO in the
severe hypertensive disorders group. One of our study’s strengths
is the design of a severity scale over which eclampsia cases can be
split into two groups. This provides a clear view of the main
predictors of worse outcomes. In other words, even though
eclampsia is a rare event, the percentage of life threatening
complications or death due to it is still extremely high in our
population.
Notwithstanding the well-established association between oc-
currence of eclampsia and maternal characteristics such as age,
ethnicity, marital status, years of education and parity, our findings
did not identify the same patterns when assessing the risk of SMO
from eclampsia [4,22,23]. One possible hypothesis is that no
matter how robust the association between the occurrence of
eclampsia and low Human Development Index (HDI) and its
indicators (e.g., low schooling and income) is, once a woman
seizures, the outcomes mainly rely on proper and timely care,
irrespective of the social and economic background characteristics
[7].
All associated complications (hemorrhage, HELLP syndrome,
severe hypertension, pulmonary edema and sepsis) were associated
with SMO. The study was originally designed to perform a
surveillance of severe complications in all pregnancies from the
participating institutions during a fixed period of time. Therefore it
was a decision to keep the data collection form as short as possible
to facilitate its implementation. Thus specific questions to go
deeper in each cause or associated factor were decided not to be
included. In addition, taking into account the fact that information
was cross-sectionally collected after the women was discharged, the
Table 1. Obstetric health indicators for eclampsia to total of cases and according to the level of income from the Brazilian regions
where the facilities are located.
Obstetric Care Indicators LI Regions N/NE/MW HI Regions S/SE Total
Maternal Near miss 48 22 70
Maternal Death 14 2 16
Live Births 39,747 42,397 82,144
SMO 62 24 86
NMM ratio/1000 LB 1.2 0.5 0.85
SMO ratio/1000 LB 1.55 0.56 1.04
NM: MD 3.4:1 11:1 4.35:1
MDI (%) 22.6 8.33 18.6
Prevalence of eclampsia per 1000 LB 8.37 2.2 5.18
SMO= severe maternal outcome, NMM=Maternal Near miss, LB = live births, MDI =maternal death index (MDI =MD/MD+NM), LI: low income, HI: high income.
doi:10.1371/journal.pone.0097401.t001
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Table 4. Variables independently associated with severe maternal outcome by Poisson multiple regression analysis (n = 321).
Factors Adjusted PR* 95% CI p
Inadequate Monitoring 2.31 1.48–3.59 0.001
ICU admission 3.61 1.77–7.35 0.001
Any previous disease 1.82 1.26–2.64 0.003
Severe Sepsis 2.75 1.35–5.61 0.007
*Considering cluster design (center/hospital), PR: prevalence ratio, CI: confidence interval, ICU= intensive care unit.
Statistical model including variables: Age, ethnicity, marital status, schooling, number of pregnancies, any previous disease, chronic hypertension, post-partum
admission, ICU admission, magnesium sulphate use, lack of medication, inadequate monitoring, delay in transfer, lack of trained staff, diagnosis delay, treatment
opportunity, inadequate management, hemorrhagic complication, HELLP syndrome, severe hypertension, pulmonary edema, severe sepsis, gestational age at birth.
doi:10.1371/journal.pone.0097401.t004
Table 3. Rate of SMO and estimated risk of SMO for eclampsia according to several characteristics concerning access to health
care facilities.
Characteristics SMO rate N % Non-SMO N % PR 95% CI
Prenatal adequacy (a)
no 1 5.9 16 94.1 0.34 0.06–1.96
yes 49 17.1 237 82.9
Post-partum admission
yes 22 26.8 60 73.2 1.44 0.97–2.15
no 64 18.6 280 81.4
ICU admission
yes 73 31.4 159 68.6 4.70 2.81–7.84
no 13 6.7 181 93.3
MgSO4 prescription
no 5 35.7 9 64.3 1.82 0.79–4.20
yes 81 19.7 331 80.3
Lack of drug (b)
yes 9 27.3 24 72,7 0.83 0.83–2.45
no 68 19.1 288 80.9
Inadequate monitoring (b)
yes 21 47.7 23 52.3 2.94 2.13–4.07
no 56 16.2 289 83.8
Delay for transfer (b)
yes 12 40.0 18 60.0 2.32 1.33–4.05
no 62 17.3 297 82.7
Lack of staff (b)
yes 17 33.3 34 66.7 1.88 1.20–2.93
no 60 17.7 278 82.3
Delay for diagnosis (b)
yes 19 37.2 32 62.8 2.29 1.42–3.69
no 55 16.3 283 83.7
Treatment opportunity (b)
no 24 35.3 44 64.7 2.27 1.48–3.46
yes 50 15.6 271 84.4
Inadequate management (b)
yes 28 29.2 68 70.8 1.86 1.33–2.60
no 46 15.7 247 84.3
SMO= severe maternal outcome (maternal near miss and maternal death), PR: prevalence ratio adjusted by cluster effect, CI: confidence interval, MgSO4: magnesium
sulphate.
Missing data from: (a) 123 cases, (b) 37 cases.
Values in bold mean they are significant.
doi:10.1371/journal.pone.0097401.t003
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information regarding the exact time on each event occurred or
each procedure was performed is not available. That is the reason
why our study could only assess use and non-use of MgSO4 and
not its appropriateness. Being a key drug to prevent seizures in
situations of severe preeclampsia, we can make the inference that
its use on the study population was almost always delayed or
inappropriate, as all the included cases had seizures [28,29].
Fourteen women (3%) did not receive MgSO4 at all, which is
noteworthy, considering it is a low-cost, effective, life-saving and
well-known drug. Our study, however, did not find a significantly
increased risk of SMO from eclampsia in cases to whom MgSO4
was not administered. The remaining 97% of cases in our study
were prescribed MgSO4 at any given time, what is a remarkably
high figure, especially when compared to the finding of 89%
MgSO4 use reported in the recently published WHO Multi-
country Survey that evaluated 29 different LMIC countries [27].
Only 8% of the cases were reported as having no access to the
drug in any given time before or after delivery.
We found a 5-fold increase in the risk of SMO among our
population with eclampsia, mostly as a consequence of delays in
diagnosis, delay in transportation. inadequate management, lack
of well-trained staff and lack of intensive care unit These variables
quantify barriers and delays for proper obstetric care, and our
findings reinforce studies that pointed those factors out as the main
challenges for improving maternal and perinatal health care in
LMIC [7,8,30,31]. The 3-fold higher risk of SMO in women that
had difficulties in accessing the obstetric ICU corroborates other
findings that had already pointed to the need for staff training and
better infrastructure for maternal facilities and obstetric ICUs for
the delivery of prompt and adequate care to severe obstetric
complications [26,28]. These categorizations were of course
attributed with the knowledge of the SMO status. If a risk of
information bias is likely to exist, this would probably be in the
way of diminishing, and not showing that these substandard care/
delays in fact occurred, considering that both local investigators
and coordinators were also part of the clinical staff of each
participating center.
To the best of our knowledge there are no published findings
concerning perinatal outcomes from two different groups of
severity (SMO and non-SMO) of eclampsia, making comparisons
difficult to be established. We found a 10% total prevalence of
perinatal mortality among cases of eclampsia. According to a
recent systematic review, a Nigerian study presenting perinatal
outcomes in eclampsia treated with MgSO4 found 30% incidence
of perinatal mortality, and a British one, 6%. Considering the 97%
use of magnesium sulphate in our cases, we could argue that our
perinatal mortality amongst cases of eclampsia is more similar to
that of the UK than to that of Nigeria [32,33].
Regarding the possible limitations of our study, the database
cannot bet understood as representative of the whole Brazilian
population. However it had a multicenter cross sectional design
and an appropriate sample size. Secondly, some maternal
characteristics are challenging to evaluate, for instance, numbers
on skin color and years of education were missing in approxi-
mately a third of the database, marital status in a fifth - yet those
variables did not appear as predictors of SMO. At the same time,
the key variables that predicted maternal SMO had less than 10%
of missing data. One of the particularities of studying NM cases is
the possibility to interview women after life-threatening events,
thus identifying breakdowns in health systems [16]. In our study
no interviews were undertaken however, but we developed a
structured form and trained investigators to gather information on
access to care not only from medical records, but also from
hospital staff, and we included an open variable that could be used
to describe a randomly peculiar characteristic that could not have
been contemplated by the form. Thus we were able to include
insights on health systems problems. As examples we could quote:
‘‘after C-section in Cabedelo city a patient was transferred to state
capital Joao Pessoa (25 km) for ICU admission at 7 pm, and died
after several seizures at 9 pm’’; or ‘‘MgSO4 administered after C-
section, patient had other seizure after procedure.’’
Brazil is a member of the BRICS nations group, which also
includes Russia, India, China and South Africa. The current
economic up growth, combined with a significant influence on
regional and global matters, bond these emerging nations. It is well
known that social and educational improvements do not always
progress hand-in-hand with the economic boom, and this is still a
challenge not only for Brazil but for the whole BRICS community.
In conclusion, improvements in social and educational struc-
tures alone will probably not lead to the needed changes on time
for the Millennium Development Goal number 5 to be achieved
by 2015. Our findings point out clearly that lower income regions
in Brazil have a worse performance in all obstetric health care
indicators among women with eclampsia. The strengthening of
health systems might be a possible strategy to reduce morbidity
and deaths in women of reproductive age and their offspring
[28,34]. It is known that social and economic determinants are
associated with higher maternal and perinatal mortality [3,32].
Waiting for changes in those patterns in order to get better
obstetric and perinatal outcomes might not be the faster route to
reduce SMO due to eclampsia. Instead, qualifying emergency
obstetric health care by promoting continued staff training and
increasing the number of well-equipped health care facilities
(especially obstetric ICU beds) are a more plausible and expedient
pathway not only for Brazil, but also for all other LMIC and
emerging nations who endeavor to relieve the burden of
eclampsia.
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